Healthcare -
Biotechnology - NASDAQ - US
$ 14.54
1.68 %
$ 948 M
Market Cap
-3.88
P/E
1. INTRINSIC VALUE
Balance Sheet
Mineralys Therapeutics, Inc.
| Current Assets | 205 M |
| Cash & Short-Term Investments | 198 M |
| Receivables | 0 |
| Other Current Assets | 7.16 M |
| Non-Current Assets | 552 K |
| Long-Term Investments | 0 |
| PP&E | 53 K |
| Other Non-Current Assets | 499 K |
| Current Liabilities | 14.6 M |
| Accounts Payable | 479 K |
| Short-Term Debt | 0 |
| Other Current Liabilities | 14.2 M |
| Non-Current Liabilities | 0 |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Mineralys Therapeutics, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 192 M |
| Operating Income | -192 M |
| Other Expenses | -14.6 M |
| Net Income | -178 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Mineralys Therapeutics, Inc.
| Net Income | -178 M |
| Depreciation & Amortization | 43 K |
| Capital Expenditures | -96 K |
| Stock-Based Compensation | 11.3 M |
| Change in Working Capital | 9.52 M |
| Others | -307 K |
| Free Cash Flow | -166 M |
Wall Street Analysts Price Targets
Mineralys Therapeutics, Inc.
Wall Street analysts predict an average 1-year price target for MLYS of $42 , with forecasts ranging from
a
low of
$30 to a high of $48 .
MLYS Lowest Price Target
Wall Street Target
30 USD
106.33%
MLYS Average Price Target
Wall Street Target
42 USD
188.86%
MLYS Highest Price Target
Wall Street Target
48 USD
230.12%
4. DIVIDEND
ANALYSIS
MLYS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Mineralys Therapeutics, Inc.
Sold
0-3 MONTHS
821 K USD 3
3-6 MONTHS
1.14 M USD 3
6-9 MONTHS
811 K USD 3
9-12 MONTHS
7.54 M USD 4
Bought
0 USD 0
0-3 MONTHS
37.2 M USD 4
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat
– The Launch-HTN trial is the largest trial of an aldosterone synthase inhibitor completed in participants with uncontrolled or treatment resistant hypertension –
globenewswire.com
- 1 week ago
Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria
– Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily achieved a 9.3 mmHg reduction in systolic blood pressure, and a 7.5 mmHg placebo-adjusted reduction (p=0.0024) at four weeks – – Lorundrostat showed a clinically meaningful reduction in the pre-defined endpoint spot urine albumin-to-creatinine ratio of 31% (p6.0 mmol/L) 0/59 (0%) 3/58 (5%) BP, blood pressure; UACR, Urine albumin-to-creatinine ratio; TEAE, Treatment-emergent adverse event * Primary endpoint. ** Cystatin-C formula, a surrogate biomarker of renal function not subject to MATE1 transport and elimination in the glomeruli of the kidney.
globenewswire.com
- 2 weeks ago
Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025)
– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world setting –
globenewswire.com
- 1 month ago
Here's Why Momentum in Mineralys Therapeutics, Inc. (MLYS) Should Keep going
Mineralys Therapeutics, Inc. (MLYS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
zacks.com
- 1 month ago
Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 3 Launch-HTN Trial at 34th European Meeting on Hypertension and Cardiovascular Protection
RADNOR, Pa., May 20, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that data from the pivotal Phase 3 Launch-HTN trial evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN) will be presented in a late-breaking clinical trials session at the 34th European Meeting on Hypertension and Cardiovascular Protection (ESH 2025), which will be held in Milan at the MICO Congress Center, on May 23-26, 2025.
globenewswire.com
- 1 month ago
Here's Why Mineralys Therapeutics, Inc. (MLYS) is a Great Momentum Stock to Buy
Does Mineralys Therapeutics, Inc. (MLYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
zacks.com
- 1 month ago
Mineralys Therapeutics, Inc. (MLYS) Q1 2025 Earnings Conference Call Transcript
Mineralys Therapeutics, Inc. (NASDAQ:MLYS ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Dan Ferry - LifeSci Advisors, IR Jon Congleton - CEO Dave Rodman - Chief Medical Officer Adam Levy - CFO Conference Call Participants Michael DiFiore - Evercore ISI Richard Law - Goldman Sachs Seamus Fernandez - Guggenheim Rami Katkhuda - LifeSci Capital Operator Good afternoon, ladies and gentlemen, and welcome to the Mineralys First Quarter 2025 Earnings Conference Call. At this time, all lines are in listen-only mode.
seekingalpha.com
- 1 month ago
Mineralys Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
– Pivotal Advance-HTN and Launch-HTN trials successfully achieved statistical significance in primary efficacy endpoints and demonstrated a favorable safety and tolerability profile – – Anticipate Explore-CKD Phase 2 trial to deliver topline data in Q2 2025 – – Initiated Explore-OSA Phase 2 Trial in Q1 2025 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa.
globenewswire.com
- 1 month ago
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
RADNOR, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Bank of America Securities 2025 Health Care Conference being held in Las Vegas on May 12-15, 2025.
globenewswire.com
- 2 months ago
Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025
RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2025, after the financial markets close on Monday, May 12, 2025.
globenewswire.com
- 2 months ago
Carl Icahn Buys More Shares, and Tesla Insider Bucks the Selling Trend
Insider buying has slowed considerably in the past week or so, due largely to the current first-quarter earnings reporting season.
247wallst.com
- 2 months ago
Mineralys Therapeutics Announces Publication of Pivotal Phase 2 Advance-HTN Results in the New England Journal of Medicine (NEJM)
– Significant blood pressure reductions among patients with uncontrolled or resistant hypertension treated with lorundrostat reinforce key role of dysregulated aldosterone in disease onset and progression –
globenewswire.com
- 2 months ago
8. Profile
Summary
Mineralys Therapeutics, Inc. MLYS
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 948 M
Dividend Yield
0.00%
Description
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Contact
150 N. Radnor Chester Rd., Radnor, PA, 19087
https://mineralystx.com
IPO
Date
Feb. 10, 2023
Employees
51
Officers
Dr. Robert McKean Ph.D.
Senior Vice President of CMC
Mr. Jeffrey N. Fellows
Senior Vice President of Regulatory Affairs
Ms. Jessica Ibbitson
Senior Vice President of Clinical Operations
Ms. Danielle Bradbury
Senior Vice President of Quality Assurance
Ms. Sarah Foster
Vice President of Human Resources
Mr. Jon Congleton
President, Chief Executive Officer & Director
Mr. Adam Scott Levy
Chief Financial Officer & Secretary
Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D.
Founder & Executive Director
Dr. David M. Rodman M.D.
Chief Medical Officer
Ms. Cindy Berejikian
Executive Vice President of Operations